Streetbeat News

Stock Prices

GM

GM shares are trading lower due to overall market weakness on debt ceiling concerns and potential impact from COVID cases in China.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 4:48 pm

TMO

Unusual options activity has been observed in Thermo Fisher Scientific (NYSE:TMO), with a bearish stance taken by a large investor. Benzinga's options scanner spotted 10 uncommon options trades, with 60% being bearish and 40% bullish. The targeted price range for TMO over the last 3 months is $440 to $530.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 4:47 pm

PLTR

Palantir shares are trading lower due to a pullback following Tuesday's strength and potential debt ceiling concerns affecting risk assets and growth stocks.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 4:44 pm

ONCY

Oncolytics Biotech shares are trading higher after JonesTrading initiated coverage on the stock with a Buy rating and announced a $9 price target.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 4:40 pm

SMFL

Smart For Life announced the launch of a new line of Sports Illustrated protein bars, leading to an increase in its share price.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 4:40 pm

HTHT

H World Group Limited shares are trading lower due to weakness in Chinese stocks.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 4:40 pm

F

Ford shares are trading lower due to overall market weakness on debt ceiling concerns and the recall of 175,000 vehicles over a seatbelt issue.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 4:35 pm

PLTR

Unusual options activity has been observed for Palantir Technologies (NYSE:PLTR) with 14 strange trades detected. Whales have been targeting a price range of $7.0 to $18.0 for the stock over the last 3 months. Analysts from Deutsche Bank, Credit Suisse, Citigroup, Goldman Sachs, and Jefferies have maintained their ratings on Palantir with varying price targets.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 4:32 pm

PHAT

Phathom Pharmaceuticals has resubmitted its FDA application for vonoprazan, an acid blocker for Erosive GERD, and raised $131M through an equity offering. The resubmission addresses concerns raised by the FDA in a Complete Response Letter.

Portfolio Pulse from Vandana Singh

May 24, 2023 | 4:31 pm

BLK

BlackRock (NYSE:BLK) has outperformed the market over the past 20 years, producing an average annual return of 14.12%. If an investor had bought $1000 of BLK stock 20 years ago, it would be worth $14,373.76 today.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 4:30 pm